A Phase 1 interventional study of Cannabidiol (CBD) in Musculoskeletal Pain, sponsored by Pure Green. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.
Sponsored by Pure Green · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Musculoskeletal Pain with a site in United States — 29 open to participants now, 36 under way, 1 of them phase 3. Musculoskeletal Pain · United States.
Among the 155 studies in Musculoskeletal Pain with a site in United States, this one is the 121st largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2019, is one of 5 in phase 1, and was the 71st registered.
516 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.
Browse Musculoskeletal Pain studies →29 of the 155 studies in Musculoskeletal Pain with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
University of Utah · Sites in United States
Ages 40–80
Butler Hospital · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Musculoskeletal Pain studies recruiting now, 29 (44%) set no upper age limit and 31 (47%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 3 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 69 across 371 interventional studies indexed under Musculoskeletal Pain.
Median enrollment 60 across the 136 interventional studies, 195 across the 19 observational. Of the 109 that completed or were terminated, 41 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 155 have an industry lead sponsor. The 10 most frequent:
Pure Green is the lead sponsor of 6 studies on the registry; none are open to participants now.
Pure Green has 1 study filed under Musculoskeletal Pain — fewer than ten, so there is no comparison to draw.
13 of the studies in Musculoskeletal Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT06867757Stanford UniversityTargeted Realtime Assessment of Chronic Pain in Youth | 2026-11 |
| NCT07393503State University of New York at BuffaloMusculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries | 2027-01 |
| NCT06886906Indiana UniversityExploring the Acute and Dynamic Relationships Between Movement and Pain in Older Adults With Musculoskeletal Pain | 2027-01-01 |
| NCT06119698Massachusetts General HospitalImproving Health for Older Adults With Pain Through Engagement | 2027-04-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 155 studies in Musculoskeletal Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
Drug: Cannabidiol (CBD)
A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
Impact of Pure Cannabidiol (CBD) tablets on safety in patient's with musculoskeletal pain using a self-reported pain scale score.
To evaluate the safety and efficacy of Pure Green Cannabidiol (CBD) sublingual tablets for the treatment of musculoskeletal pain by having patients evaluate their Numeric Pain Rating Scale (NPRS) score reported as 0-10 where 0 is no pain and 10 is the worst pain possible.
Time frame: 1 Day
To evaluate efficacy of a low dose of Cannabidiol (CBD) in the treatment of mild to moderate musculoskeletal pain.
To explore the impact of Pure Green sublingual tablets on patient self-reported Numeric Pain Rating Scale (NPRS), as a route of administration and reduction in baseline pain scores.
Time frame: 1 Day
Plan to share: No
Ran from Dec 2019 to primary completion in Dec 2019, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Pure Green